Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

Mukul Sharma, Carlos A. Molina, Kazunori Toyoda, Daniel Bereczki, Shrikant I. Bangdiwala, Scott E. Kasner, Helmi L. Lutsep, Georgios Tsivgoulis, George Ntaios, Anna Czlonkowska, Ashfaq Shuaib, Pierre Amarenco, Matthias Endres, Byung Woo Yoon, David Tanne, Danilo Toni, Laetitia Yperzeele, Paul von Weitzel-Mudersbach, Gisele Sampaio Silva, Alvaro AvezumJesse Dawson, Daniel Strbian, Turgut Tatlisumak, Jens Eckstein, Sebastián F. Ameriso, Joerg R. Weber, Else Charlotte Sandset, Nana Goar Pogosova, Pablo M. Lavados, Antonio Arauz, David Gailani, Hans Christoph Diener, Richard A. Bernstein, Charlotte Cordonnier, Anja Kahl, Grigor Abelian, Mark Donovan, Chahin Pachai, Danshi Li, Graeme J. Hankey

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial'. Together they form a unique fingerprint.

Medicine & Life Sciences